Stock Events

Stock Events

Denali Therapeutics 

$22.28
59
-$0.52-2.28% Friday 20:00
+$0.03+0.13%Friday 23:30After hours

Statistics

Day High
22.31
Day Low
22.28
52W High
27.3
52W Low
12.58
Volume
14,866
Avg. Volume
-
Mkt Cap
3.56B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.8
-0.67
-0.54
-0.41
Expected EPS
-0.405108
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-512.54MNet Income

Analyst Ratings

35.36Average Price Target
The highest estimate is 42.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DNLI. It's not an investment recommendation.
Microsoft
12
MSFT
NVIDIA
12
NVDA
AMD
12
AMD
Amazon
11
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurodegenerative diseases, directly competing with Denali's focus on neurological disorders.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals develops RNA-targeted therapies, including for neurological diseases, competing with Denali's approach.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals works on RNAi therapeutics for genetic diseases, including neurodegenerative disorders, competing with Denali's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals, while known for cystic fibrosis treatments, is expanding into gene editing for neurological diseases, posing competition to Denali.
PTC Therapeutics
PTCT
Mkt Cap5.85B
PTC Therapeutics focuses on rare disorders, including neurological diseases, directly competing with Denali's market.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, known for its broad portfolio, is increasingly focusing on treatments for neurological disorders.
Novartis
NVS
Mkt Cap292.35B
Novartis has a broad portfolio that includes treatments for neurological conditions, competing with Denali on multiple fronts.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical targets rare genetic diseases, some of which are neurological, overlapping with Denali's focus areas.
Arbutus Biopharma
ABUS
Mkt Cap1B
Arbutus Biopharma is engaged in the discovery and development of therapies for viral diseases and cancer, but its technology could be applied to neurological diseases, representing potential future competition.

About

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Show more...
CEO
Ryan J. Watts
Employees
507
Country
United States
ISIN
US24823R1059
WKN
000A2H9G8

Listings

STU
DE
4DN.STU
MU
DE
4DN.MU
SA
BR
D2NL34.SA
XNAS
US
DNLI

0 Comments

Share your thoughts

FAQ

What is Denali Therapeutics stock price today?▼
The current price of DNLI is $22.28 USD — it has decreased by -2.28% in the past 24 hours. Watch Denali Therapeutics stock price performance more closely on the chart.
What is Denali Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Denali Therapeutics stocks are traded under the ticker DNLI.
Is Denali Therapeutics stock price growing?▼
DNLI stock has fallen by -7.17% compared to the previous week, the month change is a -8.76% fall, over the last year Denali Therapeutics has showed a +44.39% increase.
What is Denali Therapeutics market cap?▼
Today Denali Therapeutics has the market capitalization of 3.56B
When is the next Denali Therapeutics earnings date?▼
Denali Therapeutics is going to release the next earnings report on November 11, 2026.
What were Denali Therapeutics earnings last quarter?▼
DNLI earnings for the last quarter are -0.68 USD per share, whereas the estimation was -0.51 USD resulting in a -32.54% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Denali Therapeutics revenue for the last year?▼
Denali Therapeutics revenue for the last year amounts to 0 USD.
What is Denali Therapeutics net income for the last year?▼
DNLI net income for the last year is -512.54M USD.
How many employees does Denali Therapeutics have?▼
As of September 05, 2026, the company has 507 employees.
In which sector is Denali Therapeutics located?▼
Denali Therapeutics operates in the Health & Wellness sector.
When did Denali Therapeutics complete a stock split?▼
Denali Therapeutics has not had any recent stock splits.
Where is Denali Therapeutics headquartered?▼
Denali Therapeutics is headquartered in SOUTH SAN FRANCISCO, United States.